| To: TokyoMex who wrote () | 2/13/2000 6:20:00 AM | | From: Walker | | | |
ACIT has doubled in a month
and has lots more to go. Co. went public a few yrs. ago at $6 and fell to .25. Last 3 quarters have been profitable and next one will be too. Stock has been moving up to a little over $1.50 in the last month and I think this one will be back to $6 in the next 9 - 12 months. Low risk, high reward play. Buyers have been accumulating anticipating the break. |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: TokyoMex who wrote () | 2/14/2000 9:58:00 AM | | From: etcobbe | | | |
RGEN - FDA approval today - One of a kind drug.
Monday February 14, 6:45 am Eastern Time
Company Press Release
SOURCE: Repligen Corporation
Repligen Issued Broad U.S. Patent For Use of Secretin In The Treatment of Autism
NEEDHAM, Mass., Feb. 14 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) today announced it was awarded a U.S. patent for the use of secretin in the treatment of autism spectrum disorder and its symptoms. U.S. patent No. 6,020,310 is entitled ``Method for assisting in differential diagnosis and treatment of autistic syndromes.'
The patent, which will remain in force until 2018, covers intravenous administration of secretin for the treatment of autism spectrum disorder and its symptoms, as well as methods where secretin is co-administered with a permeation-enhancing agent.
In March 1999, Repligen acquired exclusive rights to a series of patent applications for the use of secretin, a naturally-occurring hormone currently approved to diagnose certain gastrointestinal conditions, as a potential autism therapy. Some autistic children who have received the hormone therapeutically have made improvements in social behavior, communication, gastrointestinal function and sleep. Repligen is developing a human synthetic form of secretin for evaluation in clinical trials in pediatric autism.
``This patent allowance gives us a strong proprietary position with regard to secretin as a potential new treatment for autism, a pervasive and debilitating developmental disorder for which there are no FDA approved treatments currently available,' said Walter C. Herlihy, Ph.D., President and CEO of Repligen. ``We are currently prosecuting additional patent applications in the United States and Europe to further strengthen our position.'
The patent also discloses a previously unrecognized relationship between the response of the pancreas to secretin stimulation and autism. A recent study published in the Journal of Pediatrics (Horvath et al, Journal of Pediatrics 135 (5): 559-63) showed that 75% of autistic children with gastrointestinal symptoms had a significantly greater pancreatic response to secretin compared to children without the disorder, suggesting lack of normal secretin stimulation in this subset of autistic patients. Conducted at the University of Maryland Medical Center, the study was designed to understand the underlying biology of secretin in autism.
Autism is a neurological disorder that typically appears during the first three years of life and is characterized by defects in social interaction, communication and abnormal behavior. It is the third most common developmental disability in the United States today, affecting at least half-a-million people. There is no FDA-approved treatment for autism.
Repligen Corporation develops new drugs for autism, organ transplant and cancer. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com. |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: TokyoMex who wrote () | 2/14/2000 3:46:00 PM | | From: StalkFunder | | | |
hey, put TCBG on your watch list... if they don't go bankrupt...
it could reclaim the terrible 2's real quick
this is old Daytraders.com player's play... nothing says co won't go BK tomorrow morning! |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: TokyoMex who wrote () | 2/16/2000 2:26:00 PM | | From: beats_the_s_p500 | | | |
Analyst Report on Nova Pharmaceutical Inc. Claims Opportunity For Strategic Investors
LAKE ELSINORE, Calif., Feb. 16 /PRNewswire/ -- Nova Pharmaceutical Inc. (OTC Bulletin Board: NOVX) announced today the publication of an independent analysts report released by National Capital Securities (NCS) Research with a recommendation to Buy.
"Nova has completed its development stage and is positioned as a leader in the natural dietary and health supplement industry," says NCS. "The Company's flagship product, NxTrim is a patented, all-natural weight loss aid. According to a retail tracking report provided by the Information Resources Inc., NxTrim held the #1 ranking for diet aids in the California Drug market through 1999," NCS added.
Ralph Mann, President and CEO of Nova, said, "We believe that our company is positioned for rapid growth in the ever growing natural products industry." NCS says, "The Company is able to maintain low overhead, but still is capable of quickly responding to consumer demand."
The analyst report provides details about the nature of Nova's business, its conception, and its products and services. It also demonstrates the Company's financials and investment opinion. "We believe that Nova Pharmaceutical Inc presents a new opportunity for risk-oriented, strategic investors in this developing industry of nutritional supplements," says NCS. NCS adds, "Considering the Company's long term, steady growth outlook, we believe Nova Pharmaceutical Inc is an attractive investment and is targeting a stock price of $10 within the next 18 to 24 months."
About Nova Pharmaceutical Inc.
Nova Pharmaceutical Inc. is a publicly traded company on the OTC Bulletin Board (ticker symbol:NOVX). The company's patented weight loss product, NxTrim, achieved first year sales of $2,000,000, and is currently the number one selling diet aid in the California Drug class of trade according to data provided by Information Resources Inc.
Nova Pharmaceutical Inc is the sole manufacturer, distributor, and marketer of Gold's Gym Nutrition supplements. The company has twenty-three items under the Gold's Gym trademark.
Certain statements in this release are "forward looking" statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
--------------------------------------------------------------------------------
SOURCE: Nova Pharmaceutical Inc.
CONTACT: Ralph Mann, CEO & President, or Jim Ayres, Vice President & Secretary, both of Nova Pharmaceutical Inc., 888-495-NOVA (6682), jim@novanx.com; or Joe Stapley of Travis Morgan Securities, 949-261-2906, for Nova Pharmaceutical Inc. |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
